Hot Features
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhib... Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.47 | -9.95762711864 | 4.72 | 4.76 | 4.15 | 303608 | 4.38628684 | CS |
| 4 | -1.26 | -22.8675136116 | 5.51 | 5.62 | 4.04 | 372502 | 4.51104555 | CS |
| 12 | -1.85 | -30.3278688525 | 6.1 | 6.288 | 4.04 | 352574 | 5.27782422 | CS |
| 26 | 1.16 | 37.5404530744 | 3.09 | 6.45 | 3.05 | 427860 | 4.69096099 | CS |
| 52 | 1.01 | 31.1728395062 | 3.24 | 6.45 | 2.78 | 403176 | 4.02437257 | CS |
| 156 | -0.21 | -4.70852017937 | 4.46 | 6.45 | 2.3 | 367237 | 3.63516629 | CS |
| 260 | -17.65 | -80.5936073059 | 21.9 | 46.9099 | 2.3 | 760051 | 11.31803374 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.